NDC product
WELIREG
NDC 0006-5331 · Merck Sharp & Dohme LLC
Key facts
| Product NDC | 0006-5331 |
|---|---|
| Proprietary name | WELIREG |
| Nonproprietary name | belzutifan |
| Substances | BELZUTIFAN |
| Dosage form | TABLET, FILM COATED |
| Route | ORAL |
| Labeler | Merck Sharp & Dohme LLC |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA215383 |
| Pharmacologic classes | Cytochrome P450 3A4 Inducers [MoA], Hypoxia-inducible Factor 2 alpha Inhibitors [MoA], Hypoxia-inducible Factor Inhibitor [EPC] |
| Marketing start | Aug 13, 2021 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: